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AF = atrial fibrillation.
Available online http://cvm.controlled-trials.com/content/2/2/067
During the past 5 years, great strides have been made in
unraveling the complex interplay of factors that are respon-
sible for initiating and maintaining atrial fibrillation (AF).
According to our present understanding of AF (which is
still in its infancy), AF is initiated by a number of possible
supraventricular tachyarrhythmias, most commonly prema-
ture atrial contractions or rapid, often nonsustained, atrial
tachycardias that arise from the pulmonary veins and, less
commonly, nonpulmonary vein sites [1–3]. These are gen-
erally ‘focal’ arrhythmias; that is, they can be mapped to
relatively small areas of less than a few millimeters. These
focal triggering arrhythmias may initiate true AF, which is
due to a complex series of multiple wavefronts that simul-
taneously activate both the right and left atria in a non-
repeating pattern or in minimally repeating patterns [4].
The ability to maintain AF is dependent on a number of
factors, such as atrial size, mass, stretch and fibrosis, het-
erogeneity of activation and repolarization, continued acti-
vation of triggering arrhythmias to prevent organization and
termination, and autonomic tone [5,6]. If the appropriate
substrate is not present, AF once initiated will not be main-
tained and will spontaneously terminate. Thus, the interac-
tion between initiators and substrate determine whether
the clinical presentation is that of paroxysmal or persistent
AF. In addition, a host of factors serve to modulate both the
initiators and substrate of AF, including autonomic tone,
volume status, body position, drugs, and electrical and
structural remodeling that occur as a direct consequence
of AF [5–7]. Thus, AF can be considered as a complex
interplay of initiators, substrate, and modulating factors.
The goal of AF ablation approaches may be either palliative
or curative. Palliative procedures are aimed at nonpharma-
cological rate control by creation of complete heart block
(AV node ablation with permanent pacemaker placement)
or high-grade AV block (AV nodal modification without
pacemaker). These approaches obviously do not prevent
AF from continuing or recurring, not do they eliminate the
need for antiarrhythmic drugs or anticoagulation. More
recently, approaches have been developed to prevent
recurrent AF. These curative ablation approaches for AF
are aimed at either eliminating or isolating AF initiators,
and/or alterating of atrial substrate in order to prevent the
maintenance of AF. Either approach should prevent recur-
rence of sustained AF. What limits all of these attempts at
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AF ablation is that we do not understand the full range of
events that initiate and/or maintain AF. Nonetheless,
progress has been made toward successful ablation of AF
in a number of clinical conditions, such as AF in the setting
of no or minimal heart disease. These attempts have signifi-
cantly contributed to our present understanding of the
pathogenesis of AF. The question presented by this rapid
growth in our knowledge is whether AF ablation is suffi-
ciently mature to serve as frontline therapy for AF, with
widespread application within the community.
Ablation of focal initiators of AF
The greatest advances have been made in the ablation of
the focal atrial arrhythmias that are responsible for initiat-
ing and, in some cases, maintaining AF. Although regular
rapid atrial tachyarrhythmias were shown in animal models
to be possible causes of AF as long as 50 years ago [8]
and were observed to be the initiating events of AF in
humans 30 years ago [9], the precise nature of these ini-
tiators in humans remained poorly understood until
recently. Haissaguerre and coworkers [1,3] and others [2]
recently showed that atrial tachycardias, which arise most
typically within the residual left atrial musculature that sur-
rounds the pulmonary veins as they approach the left
atrium, are responsible for initiating most AF, at least in
those patients with no or minimal heart disease [1–3].
Ablation of these atrial tachycardias has been shown to
cure AF in patients with frequent atrial ectopy and insignif-
icant cardiac disease. A number of retrospective and
uncontrolled studies [1–3] have shown that focal AF abla-
tion may be curative in 60–85% of these patients. Vari-
ables that are related to success rates include patient
inclusion criteria, ablation approaches, severity of underly-
ing atrial disease, number of initiator sites, and the dura-
tion of AF. Although none of these studies had parallel
control groups, most of the patients had high frequencies
of AF before ablation, and the lack of symptomatic
episodes after successful ablation strongly suggests that
the procedure is effective.
Limitations of focal AF ablation
Despite the encouraging initial reports, ablation of focal ini-
tiators of AF is still in its infancy. Several issues need to be
addressed. To date, only heavily selected groups of
patients have been studied. Typically, these groups have
included younger patients with no or minimal heart disease,
and with paroxysmal AF, high-density atrial ectopy, and a
priori assessment that they had ‘focal AF’. The efficacy of
these procedures applied to unselected patient popula-
tions with paroxysmal AF is not known, and only limited
data are available regarding efficacy for patients with per-
sistent and chronic AF. Preliminary studies that evaluated
patients with persistent AF [3] have demonstrated more
modest results, and preliminary results for patients with
chronic AF are very disappointing. Furthermore, there is
little available data regarding the efficacy of the procedure
in the setting of significant cardiac disease. More informa-
tion regarding optimal patient selection for focal AF abla-
tion approaches is needed.
In reported studies regarding the ablation of AF initiators,
follow up is limited to several months, or at best a couple of
years. Insensitive follow-up techniques may result in con-
siderable errors of omission, and may overestimate long-
term cure rates. In addition, conversion of symptomatic to
asymptomatic AF could occur as a consequence of these
procedures and not be detected on simple symptom
reviews during follow up. Appropriate means for long-term
follow up in these trials needs to be determined. However,
the limitations of random 24-h Holter recordings once
every month or a few seconds of event recordings every
week are obvious in a disease process that may manifest
itself only for a few hours every other month. Recently
developed arrhythmia-triggered (as well as patient-acti-
vated) event monitors may be useful in this situation for
more precise determination of whether the end result is
truly curative or just quantitative suppressive of AF events.
Given the relatively short duration of available follow up for
focal AF ablation approaches, we do not know whether
these procedures will continue to protect patients over
years and decades. Importantly, we do not understand
either the pathogenesis or the natural history of these initi-
ating arrhythmias. Whether additional initiators will evolve
over the years is not known, and will remain unknown until
long-term follow-up study results are available. In addition,
although most of the initiating arrhythmias appear to arise
within the pulmonary veins, the applicability of this
assumption to larger, more varied groups of patients with
AF remains to be tested. Thus, the efficacy of empiric pul-
monary vein isolation procedures in the diversity of
patients with AF is unknown.
Of major concern with pulmonary vein isolation or ablation
procedures is the occurrence of partial or complete steno-
sis of the pulmonary veins [10]. Symptomatic stenosis is
detected in fewer than 5% of patients, and is due to com-
plete or near-complete stenosis of one or more pulmonary
vein [1–3]. However, up to 42% of patients may have
some degree of pulmonary vein stenosis [2]. Although tol-
erance of these mild degrees of stenosis is excellent, the
long-term sequelae are not known. Cases of pulmonary
hypertension as a consequence of pulmonary vein ablation
and stenosis have been reported [11]. Although stenting
of the stenosis may be effective acutely, the long-term
patency of these stents is unknown.
Catheter-based maze procedures
Even less is known about procedures that are aimed at
eliminating the ability of the atria to maintain AF. Curative
ablation of AF can be achieved during open-heart surgery
by surgically isolating the pulmonary veins from the atria,c
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dividing the right and left atria into several connected,
dead-end corridors in continuity with the sinus node, and
excising the atrial appendages [12]. The surgically created
lines of conduction block created by the connected dead-
end corridors prevent the wandering wavelets of re-entry
during AF from sustaining. The surgical maze procedures
have been shown to be effective treatments for paroxys-
mal, persistent, and chronic AF. Although open-chest pro-
cedures are required, the cure rate is approximately 85%,
with substantial morbidity and some mortality attendant to
the surgical procedures [12]. Following these principles,
multiple investigators have shown [13–16] that creation of
multiple long lines of conduction block in both the right
and left atria to simulate in part the surgical maze proce-
dure may cure some AF patients. Although the initial retro-
spective analyses looked exceptionally promising, with up
to 87% cure rates [16], two ongoing prospective studies
[17,18] of biatrial lesion sets have been less optimistic,
with success rates of approximately 50% or less. Although
a greater number of patients have less frequent AF on
antiarrhythmic drugs, this end-point is subjective, is diffi-
cult to quantify, and is subject to bias. More importantly,
rates of major complications in the prospective studies
have been unacceptably high, occurring in approximately
one-quarter of patients. Although symptomatic control
with continued antiarrhythmic drug therapy can be
achieved in the majority of patients, the high rates of
serious complications significantly limit application of
these procedures to only a few, heavily symptomatic
patients, and hamper enrollment of patients in studies
evaluating new technologies that are aimed at simplifying
the procedure. Limitation of the linear lesions to the right
atrium greatly simplifies the procedure and avoids the
potential risks associated with creation of linear lesions in
the left atrium. Right-atrium-only linear lesion sets rarely
cure patients with paroxysmal AF, however, and are inef-
fective in chronic AF [16,19,20]. Selected patients with
paroxysmal AF may have high rates of cure [20], but the
criteria for selection of these patients are not well defined.
Prophylactic anticoagulation post-ablation
By eliminating AF with ablation of either the initiators or
substrate, it is assumed that the long-term need for
chronic anticoagulation for stroke prophylaxis is avoided.
Although uncontrolled data from patients after surgical
maze procedures appears to support this contention [21],
there are no long-term data regarding AF ablation proce-
dures. Anecdotal cases of late postablation cerebro-
embolic events have been reported. These may be due to
emboli from a number of sources, including the following:
pre-existing left atrial thrombi; lesion-related thrombus in
the left atrium or pulmonary veins; thrombus from dimin-
ished left atrial transport; paradoxic emboli across persis-
tence flow communications from trans-septal access sites;
continued undetected atrial fibrillation; and valvular or
peripheral vascular disease. Thus, successful ablation
does not necessarily exclude the need for chronic anti-
coagulation. Further data from the individual procedures
are needed in order to determine the advisability of with-
drawal of anticoagulation after AF ablation.
What needs to be done
As with all issues regarding nonpharmacologic therapy,
prospective, controlled trials comparing various ablation
approaches with traditional antiarrhythmic drug therapy or
atrioventricular nodal ablation and pacemaker placement
need to be performed. These trials can address such
issues as comparative efficacy, complication rates, quality
of life indices, and cost-effectiveness. Because mortality
rates for conventional and new ablation approaches are
very low, it is unlikely that trials of sufficient power will ever
be performed to determine whether mortality benefits
exist. In addition, there are several approaches for treat-
ment of initiators. These include ablation directed at spon-
taneously discharging foci, isolation of pulmonary veins
with spontaneously occurring arrhythmias, and empiric
pulmonary vein isolation of all pulmonary veins with a mus-
cular sleeve, regardless of whether an arrhythmogenic
focus is identified. Likewise, there are different
approaches for performing linear lesions for substrate
modification. Various technologies have been or are being
developed to ablate initiators and modify substrate. As
these approaches are developed, prospective compar-
isons are needed to determine which approaches and
technologies have the greatest efficacy and safety.
It is clear from the available information that curative ablation
approaches for AF are rapidly advancing, but too little is
known at present to advocate widespread implementation.
In particular, given the potential for serious complications,
even with ablation of AF initiators in healthy individuals, it is
difficult to advocate ablation as frontline therapy in advance
of traditional pharmacologic approaches. Furthermore, the
procedures are technically difficult, arduous, time-consum-
ing, and are not cost-effective. Given the risks of serious
complications, even in experienced hands, a loud note of
caution must be expressed concerning widespread applica-
tion by individuals who are inexperienced in technical
aspects of the procedure, such as trans-septal catheteriza-
tion, pulmonary vein ablation, and linear lesion creation in
the left atrium. Appropriate educational guidelines need to
be established in order to ensure safe application of these
approaches in the community.
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